133 related articles for article (PubMed ID: 32535096)
21. Anti-inflammatory role of DPP-4 inhibitors in a nondiabetic model of glomerular injury.
Higashijima Y; Tanaka T; Yamaguchi J; Tanaka S; Nangaku M
Am J Physiol Renal Physiol; 2015 Apr; 308(8):F878-87. PubMed ID: 25656369
[TBL] [Abstract][Full Text] [Related]
22. Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism.
Ahrén B; Foley JE
Diabetologia; 2016 May; 59(5):907-17. PubMed ID: 26894277
[TBL] [Abstract][Full Text] [Related]
23. Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs.
Deacon CF; Wamberg S; Bie P; Hughes TE; Holst JJ
J Endocrinol; 2002 Feb; 172(2):355-62. PubMed ID: 11834453
[TBL] [Abstract][Full Text] [Related]
24. Evidence for neural contribution to islet effects of DPP-4 inhibition in mice.
Ahlkvist L; Omar B; Pacini G; Ahrén B
Eur J Pharmacol; 2016 Jun; 780():46-52. PubMed ID: 26997369
[TBL] [Abstract][Full Text] [Related]
25. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).
Thornberry NA; Gallwitz B
Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):479-86. PubMed ID: 19748065
[TBL] [Abstract][Full Text] [Related]
26. Cross-talk between the dipeptidyl peptidase-4 and stromal cell-derived factor-1 in stem cell homing and myocardial repair: Potential impact of dipeptidyl peptidase-4 inhibitors.
Anderluh M; Kocic G; Tomovic K; Kocic R; Deljanin-Ilic M; Smelcerovic A
Pharmacol Ther; 2016 Nov; 167():100-107. PubMed ID: 27484974
[TBL] [Abstract][Full Text] [Related]
27. Ezetimibe stimulates intestinal glucagon-like peptide 1 secretion via the MEK/ERK pathway rather than dipeptidyl peptidase 4 inhibition.
Chang E; Kim L; Choi JM; Park SE; Rhee EJ; Lee WY; Oh KW; Park SW; Park DI; Park CY
Metabolism; 2015 May; 64(5):633-41. PubMed ID: 25704082
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.
Pratley RE; Salsali A
Curr Med Res Opin; 2007 Apr; 23(4):919-31. PubMed ID: 17407649
[TBL] [Abstract][Full Text] [Related]
29. Membrane localization of 3-phosphoinositide-dependent protein kinase-1 stimulates activities of Akt and atypical protein kinase C but does not stimulate glucose transport and glycogen synthesis in 3T3-L1 adipocytes.
Egawa K; Maegawa H; Shi K; Nakamura T; Obata T; Yoshizaki T; Morino K; Shimizu S; Nishio Y; Suzuki E; Kashiwagi A
J Biol Chem; 2002 Oct; 277(41):38863-9. PubMed ID: 12147684
[TBL] [Abstract][Full Text] [Related]
30. Glucagon-like peptide-1 protects hippocampal neurons against advanced glycation end product-induced tau hyperphosphorylation.
Chen S; An FM; Yin L; Liu AR; Yin DK; Yao WB; Gao XD
Neuroscience; 2014 Jan; 256():137-46. PubMed ID: 24183963
[TBL] [Abstract][Full Text] [Related]
31. The emerging role of dipeptidyl peptidase-4 inhibitors in cardiovascular protection: current position and perspectives.
Wang XM; Yang YJ; Wu YJ
Cardiovasc Drugs Ther; 2013 Aug; 27(4):297-307. PubMed ID: 23645229
[TBL] [Abstract][Full Text] [Related]
32. Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice.
Waget A; Cabou C; Masseboeuf M; Cattan P; Armanet M; Karaca M; Castel J; Garret C; Payros G; Maida A; Sulpice T; Holst JJ; Drucker DJ; Magnan C; Burcelin R
Endocrinology; 2011 Aug; 152(8):3018-29. PubMed ID: 21673098
[TBL] [Abstract][Full Text] [Related]
33. DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control.
Bae EJ
Arch Pharm Res; 2016 Aug; 39(8):1114-28. PubMed ID: 27502601
[TBL] [Abstract][Full Text] [Related]
34. Hematopoietic cell- versus enterocyte-derived dipeptidyl peptidase-4 differentially regulates triglyceride excursion in mice.
Varin EM; Hanson AA; Beaudry JL; Nguyen MA; Cao X; Baggio LL; Mulvihill EE; Drucker DJ
JCI Insight; 2020 Aug; 5(16):. PubMed ID: 32663193
[TBL] [Abstract][Full Text] [Related]
35. Phospho-GSK-3β is involved in the high-glucose-mediated lipid deposition in renal tubular cells in diabetes.
Liu W; Hao J; Zhu L; Li F; Liu Q; Liu S; Zhao S; Li H; Duan H
Int J Biochem Cell Biol; 2013 Sep; 45(9):2066-75. PubMed ID: 23880101
[TBL] [Abstract][Full Text] [Related]
36. Combined treatment of dipeptidyl peptidase-4 inhibitor and exercise training improves lipid profile in KK/Ta mice.
Tanimura Y; Aoi W; Mizushima K; Higashimura Y; Naito Y
Exp Physiol; 2019 Jul; 104(7):1051-1060. PubMed ID: 31020720
[TBL] [Abstract][Full Text] [Related]
37. Rg1 protects H9C2 cells from high glucose-/palmitate-induced injury via activation of AKT/GSK-3β/Nrf2 pathway.
Yu H; Zhen J; Yang Y; Du J; Leng J; Tong Q
J Cell Mol Med; 2020 Jul; 24(14):8194-8205. PubMed ID: 32548942
[TBL] [Abstract][Full Text] [Related]
38. Pharmacological profiles of gemigliptin (LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo.
Kim SH; Jung E; Yoon MK; Kwon OH; Hwang DM; Kim DW; Kim J; Lee SM; Yim HJ
Eur J Pharmacol; 2016 Oct; 788():54-64. PubMed ID: 27298192
[TBL] [Abstract][Full Text] [Related]
39. Neprilysin inhibition in mouse islets enhances insulin secretion in a GLP-1 receptor dependent manner.
Esser N; Barrow BM; Choung E; Shen NJ; Zraika S
Islets; 2018; 10(5):175-180. PubMed ID: 30142012
[TBL] [Abstract][Full Text] [Related]
40. An interaction between glucagon-like peptide-1 and adenosine contributes to cardioprotection of a dipeptidyl peptidase 4 inhibitor from myocardial ischemia-reperfusion injury.
Ihara M; Asanuma H; Yamazaki S; Kato H; Asano Y; Shinozaki Y; Mori H; Minamino T; Asakura M; Sugimachi M; Mochizuki N; Kitakaze M
Am J Physiol Heart Circ Physiol; 2015 May; 308(10):H1287-97. PubMed ID: 25747753
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
